Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes

References

• BACHMANN, K. A., C0u, C. A. and GREEAR, V., 1992, In vivo evidence that ethosuximide is a substrate for cytochrome P450 IIIA. Pharmacology, 45, 121–128.
   Google Scholar
• BACHMANN, K. A. and JAUREGUI, L., 1993, Use of single clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica, 23, 307–315.
   PubMed Web of Science ®Google Scholar
• DIEM, K. AND LENTNER, C. (eds), 1970, Documenta Geigy. Scientific Tables, 7th edn (Basle: Ciba-Geigy). GENTEST CORPORATION, 1997, 1996–1997 Catalog (Woburn: Gentest Corp.).
   Google Scholar
• GIACCONE, M., BARTOLI, A., GATTI, G., MARCHISELLI, R., PISANI, F., LATELLA, M. and PERUCCA, E., 1996, Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. British Journal of Clinical Pharmacology, 41, 575–579.
   PubMedGoogle Scholar
• HORNING, M. G., STRATTON, C., NOWLIN, J., HARVEY, D. J. and HILL, R. M., 1973, Metabolism of 2-ethyl-2-methylsuccinimide (ethosuximide) in the rat and human. Drug Metabolism and Disposition, 3, 569–576.
   Google Scholar
• HUNT, C., WATKINS, P., SAENGER, P., STAVE, G., BARLASCINI, N., WATLINGTON, C., WRIGHT, J., JR and GUZELIAN, P., 1992, Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clinical Pharmacology and Therapeutics, 51, 18–23.
   PubMed Web of Science ®Google Scholar
• IWATSUBO, T., HIROTA, N., 001E, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A. and SUGIYAMA, Y., 1997, Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics, 73, 147–171.
   Google Scholar
• KINIRONS, M., OSHEA, D., DOWNING, T., FITZWILLIAM, A., JOLLENBECK, L., GROOPMAN, J., WILKINSON, G. and WOOD, A., 1993, Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clinical Pharmacology and Therapeutics, 54, 621–629.
   PubMedGoogle Scholar
• KINIRONS, M., OSHEA, D., Kim, R., GROOPMAN, J., THUMMEL, K., WOOD, A. J. and WILKINSON, G. R., 1999, Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P453A. Clinical Pharmacology and Therapeutics, 66, 224–231.
   PubMed Web of Science ®Google Scholar
• KRIVORUK, Y., KINIRONS, M., WOOD, A. and WOOD, M., 1994, Metabolism of cytochrome P4503A substrates in vivo administered by the same route: Lack of correlation between alfentanil clearance and erythromycin breath test. Clinical Pharmacology and Therapeutics, 56, 608–614.
   PubMedGoogle Scholar
• LEWIS, D. F. V., 2000, On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Towards the prediction of human P450 substrate specificity and metabolism. Biochemical Pharmacology, 60, 293–306.
   PubMed Web of Science ®Google Scholar
• MAURER, H. H., 1990, Detection of anticonvulsants and their metabolites in urine within a general unknown analysis procedure using computerized gas chromatography-mass spectroscopy. Archives of Toxicology, 64, 554–561.
   PubMedGoogle Scholar
• MILLERSHIP, J. S., COLLIER, P. S., HAMILTON, J. T. G., MCROBERTS, W. C. and MISFUD, J., 1995, Chiral aspects of the metabolism of ethosuximide. Chirality, 7,173–180.
   Google Scholar
• MILLERSHIP, J. S., MISFUD, J. and COLLIER, P. S., 1993, The metabolism of ethosuximide. European Journal of Drug Metabolism and Pharmacokinetics, 18, 349–353.
   PubMedGoogle Scholar
• PAINE, M., SHEN, D., KUNZE, K., PERKINS, J., MARSH, C., MCVICAR, J., BARR, D., GILLIES, B. and THUMMEL, K., 1996, First-pass metabolism of midazolam by the human intestine. Clinical Pharmacology and Therapeutics, 60, 14–24.
   PubMed Web of Science ®Google Scholar
• PETTERSEN, J. E., 1980, Studies on the metabolism of the antiepileptic drug 2-ethy1-2-methylsuccinimide by combined GCMS. Advances in Mass Spectroscopy, 8B, 1291–1297.
   Google Scholar
• PISANI, F. and BIALER, M., 1995, Ethosuximide chemistry and biotransformation. In R. H. Levy, R. H. Mattson and B. S. Meldrum (eds), Antiepileptic Drugs (New York: Raven), pp. 655–665.
   Google Scholar
• SARVER, J. G., BACHMANN, K. A., ZHU, D. and Kms, W. A., 1998, Ethosuximide is primarily metabolized by CYP3A when incubated with isolated rat liver microsomes. Drug Metabolism and Disposition, 26, 78–82.
   PubMedGoogle Scholar
• SHIMADA, T., TSUMURA, F. and YAMAZAKI, H., 1999, Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metabolism and Disposition, 27, 1274–1280.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• SLAMA, J., HANCOCK, J., RHO, T., SAMBUCETTI, L. and BACHMANN, K. 1998, Influence of Some novel N-substituted azoles and pyridines on rat hepatic CYP3A activity. Biochemical Pharmacology, 55, 1881–1892.
   PubMedGoogle Scholar
• STEIN, C. M., KINIRONS, M., PINCUS, T., WILKINSON, G. and WOOD, A., 1996, Comparison of the dapsone recovery ratio and erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clinical Pharmacology and Therapeutics, 59, 47–51.
   PubMedGoogle Scholar
• THUMMEL, K., OSHEA, D., PAINE, M., SHEN, D., KUNZE, K., PERKINS, J. and WILKINSON, G., 1996, Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapeutics, 59, 491–502.
   PubMed Web of Science ®Google Scholar
• THUMMEL, K. E. and SHEN, D., 2001, Design and optimization of dosage regimens: pharmacokinetic data. In J. Hardman, L. Limbird and A. Goodman Gilman (eds), The Pharmacological Basis of Therapeutics, 10th edition (New York: McGraw-Hill), pp. 1917–2023.
   Google Scholar
• THUMMEL, K., SHEN, D., PODOLL, T., KUNZE, K., TRAGER, W., BACCHI, C., MARSH, C., MCVICAR, J., BARR, D., PERKINS, J. and CARITHERS, R., 1994b, Use of midazolam as a human cytochrome P4503A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. Journal of Pharmacology and Experimental Therapeutics, 271, 557–566.
   PubMed Web of Science ®Google Scholar
• THUMMEL, K. E., SHEN, D., PODOLL, T., KUNZE, K., TRAGER, W., HARTWELL, P., RAISYS, V., MARCH, C., MCVICAR, J., BARR, D., PERKINS, J. and CARITHERS, R., 1994a, Use of midazolam as a human CYP3A probe: I. in vitro—in vivo correlations in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics, 271, 549–556.
   PubMed Web of Science ®Google Scholar
• VENKATAKRISHNAN, K., VON MOLTKE, L., COURT, M., HARMATZ, J., CRESPI, C. and GREENBLATT, D., 2000, Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metabolism and Disposition, 28, 1493–1504.
   PubMed Web of Science ®Google Scholar
• WATKINS, P., 1994, Noninvasive tests of CYP3A enzymes. Pharmacogenetics, 4, 171–184.
   PubMedGoogle Scholar
• WATKINS, P., TURGEON, D., SAENGER, P., LOWN, K., KOLARS, J., HAMILTON, T., FISHMAN, K., GUZELIAN, P. and VOORHEES, J., 1992, Comparison of urinary 6-13-cortisol and erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clinical Pharmacology and Therapeutics, 52, 265–273.
   PubMed Web of Science ®Google Scholar